Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086328 | 0.86 | POLB (0.47) | POLBKMT2ALMNAMAPTMEN1 | |
| SCHEMBL1086782 | 0.85 | TACR2 (0.42) | TACR2TACR1 | |
| SCHEMBL1085948 | 0.85 | POLB (0.46) | POLBKMT2ALMNAMAPTMEN1 | |
| SCHEMBL1086775 | 0.83 | NPSR1 (0.45) | KMT2AMEN1ALDH1A1PKMTACR2 | |
| Beclamide SCHEMBL1086331 | 0.82 | TACR2 (0.40) | MAPTTACR2TACR1SMN1; SMN2SIGMAR1 | |
| SCHEMBL1086172 | 0.82 | TACR2 (0.42) | ALDH1A1TACR2TACR1SIGMAR1 | |
| SCHEMBL1086185 | 0.81 | MEN1 (0.45) | POLBKMT2ALMNAMAPTMEN1 | |
| SCHEMBL1086781 | 0.79 | TACR2 (0.40) | TACR2TACR1 | |
| SCHEMBL4257388 | 0.78 | ALDH1A1 (0.48) | KMT2ALMNAMAPTMEN1ALDH1A1 | |
| SCHEMBL1086088 | 0.77 | ALDH1A1 (0.48) | LMNAALDH1A1TACR2TACR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | claimed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | claimed |
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | POLB 2624/4885KMT2A 4267/4885LMNA 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.